SOURCE: Active Biotech

February 10, 2011 02:39 ET

Active Biotech AB Year-end Report January - December 2010

LUND, SWEDEN--(Marketwire - February 10, 2011) -



· Laquinimod - positive results presented from ALLEGRO Phase III trial

· TASQ - pivotal Phase III study initiated in the first quarter of 2011

· ANYARA - ongoing Phase III study expected to be concluded in 2012

· 57-57 - recommended Orphan Medicinal Product Status

· ISI - project proceeding according to plan

· RhuDex™ - preparations for continued clinical development in progress

· Net sales SEK 11.4 M (10.8)

· Operating loss SEK 229.0 M (loss: 219.6)

· Loss after tax SEK 221.1 (loss: 224.0)

· Loss per share for the period amounted to 3.38 (loss: 3.81)

· Private placement of SEK 375 M completed after the end of the period


This report is also available at www.activebiotech.com


Active Biotech AB Year-end Report Jan-Dec 2010: http://hugin.info/1002/R/1487271/422685.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1487271]

Contact Information

  • For further information, please contact:

    Tomas Leanderson
    President and CEO
    Tel: +46 (0)46-19 20 95

    Goran Forsberg
    VP Investor Relations & Business Development
    Tel: +46 (0)46-19 11 54

    Hans Kolam
    CFO
    Tel. +46 (0)46-19 20 44

    Active Biotech AB
    (Corp. Reg. No. 556223-9227)
    PO Box 724, SE-220 07 Lund
    Tel: +46 (0)46-19 20 00
    Fax: +46 (0)46-19 11 00